SCYNEXIS Prices the Split, Not the Runway

Summary: SCYX last traded at $0.7009 in the live market-data snapshot checked on May 27, 2026 at 21:35:35 UTC. SCYNEXIS will effect a 1-for-8 reverse split after the close on May 29, and the stock will begin split-adjusted trading on June 1. That optics event is usually poisonous in microcap biotech. Here the disagreement is narrower: the company says it had $72.4 million of cash, cash equivalents and investments at March 31, plus about $16.0 million of additional private-placement proceeds received on April 1, extending runway to mid-2029. Using the company-disclosed 79.5 million pre-split common shares, the current quote implies a basic equity value near $55.7 million, well below that cash-and-investments runway frame. [1][2][3]

Opportunity Ranking

U.S.-only screen, per user scope. Creative search lanes used: reverse-split forced-screen failures, stale market-cap feeds after PIPE closings, below-NAV BDC vote mechanics, rumor-premium fade setups, and merger-vote spreads. Current-week and repo-wide title scans rejected duplicate or adjacent topics including AIV, TYG, FSK, BIRD, FREVS, SEER, GOSS, STRS, ASTS, GDOT, NHIC, and BRNS.

Rank	Idea	Discovery Lane	Why It May Be Best Now	Evidence Freshness	Catalyst Window	Near-Term >5% Move Case	Asymmetry	Main Reason to Reject
1	SCYNEXIS prices the split, not the runway	U.S. biotech / reverse split / funded optionality / screen failure	`SCYX` trades at $0.7009 before a 1-for-8 split even though the company says March cash and investments plus the April 1 proceeds support runway to mid-2029. The split-adjusted quote is only about $5.61, while post-April cash and investments are about $8.90 per post-split basic share before burn and liabilities. [1][2][3]	High. Split release dated May 22; Q1 update dated May 11; live price checked May 27. [1][2][3]	Immediate. Split effective May 29, split-adjusted trading starts June 1, IV SCY-247 topline data expected in Q3 2026. [2][3]	A >5% jump can occur if post-split trading re-anchors from sub-dollar optics to funded-runway math, or if investors stop using stale basic market-cap screens.	Positive skew, but biotech and reverse-split selling risk remain real.	Selected.
2	Lantheus prices a process, not a bid	U.S. medtech / takeover rumor / event fade	`LNTH` still carries a sale-process premium after reported Curium interest, but there is no confirmed definitive proposal in company filings. [4]	Medium. The price is fresh and the press report is fresh, but the central fact is not primary-source confirmed. [1][4]	Soft but near-term. Silence, confirmation, or a competing report could move the stock quickly.	A >5% dump is plausible if rumor premium bleeds out.	Tradeable and liquid, but the source hierarchy is weaker.	Rejected because the thesis rests too heavily on press reporting.
3	Carlyle Secured Lending prices dilution authority as damage	U.S. BDC / below-NAV vote / credit discount	`CGBD` trades at a deep discount while asking holders for below-NAV issuance authority, but that permission can be a governance tool rather than an imminent dilution plan. [5]	Medium. Proxy and Q1 context are current, but the actual use of authority is conditional. [5]	June 9, 2026 meeting. [5]	A >5% jump or dump is possible around the vote, but the path depends on credit marks and investor interpretation.	Real, but less clean than `SCYX` because the vote does not itself close the valuation gap.	Rejected because the catalyst is permission, not action.
4	FONAR prices completion risk inside a $19 cash vote	U.S. merger / cash vote / spread	`FONR` trades near the $19.00 merger consideration before a special meeting. [6]	High, but the spread is thin. [1][6]	May 28, 2026 meeting. [6]	A break can move the stock more than 5%, but the positive spread is too small.	Poor upside unless the deal fails and one has already expressed a negative view.	Rejected on payoff architecture.

Selected opportunity: SCYNEXIS (SCYX) common stock, long.

Why this one now: The split date is immediate, the market-data screen is noisy because the company’s post-financing share count is higher than the quote feed’s market-cap denominator, and the cash runway is documented by the company’s own release and filings. [1][2][3]

Why it can jump more than 5% soon: The event is visible: May 29 split effectiveness and June 1 split-adjusted trading. A re-anchor from sub-dollar distress optics to a roughly $5.61 split-adjusted stock with a stated mid-2029 runway can plausibly move the common more than 5% in days. Evidence quality is medium-high: price, split, balance sheet, and runway are sourced; post-split holder flow is not.

What should surprise the reader: The surprising part is not that a reverse-split biotech looks ugly. Most do. The surprise is that the ugliness may be causing investors to price the split as if it changes the balance sheet, when the company has just financed itself into a multi-year runway.

The Setup

SCYNEXIS is not a clean large-cap mispricing. It is a small biotech where the quote, share count, split mechanics, and runway have stopped telling the same story.

The company will combine every 8 common shares into 1 share after the close on May 29, 2026. It expects Nasdaq trading on a split-adjusted basis to start on June 1 under the same ticker, SCYX. The stated reason is compliance with Nasdaq's minimum bid price requirement. [2]

That alone usually deserves skepticism. Reverse splits often mark capital-market damage, shareholder fatigue, and future financing risk. The market is right to punish many of them.

The question is whether this one has been punished as a split story while the cash runway and pipeline calendar say something less distressed.

The Mispricing

The market appears to be pricing SCYX as a sub-dollar reverse-split biotech that still needs external rescue capital.

The filings point to a more specific disagreement. SCYNEXIS completed a private placement with about $37.2 million of net proceeds, received about $24 million by March 31 and about $16 million more on April 1, and ended Q1 with $72.4 million of cash, cash equivalents and investments. Management says the March balance plus the April 1 proceeds extends cash runway to mid-2029. [3]

At $0.7009, using the company’s own 79.5 million pre-split common share count from the split release gives a basic equity value of roughly $55.7 million. The split-adjusted equivalent is about $5.61 per share. Post-April cash and investments of roughly $88.4 million equal about $1.11 per pre-split share, or $8.90 per post-split basic share, before adjusting for burn, liabilities, warrants, and pipeline risk. [1][2][3]

The finance quote surface showed a market capitalization near $35.7 million, but that appears to use an older share denominator. I do not use it for valuation. The live price is useful. The stale market-cap screen is part of the possible mispricing. [1][2]

Price

Market Level	Value	Timestamp / Source	Why It Matters
`SCYX` latest price	$0.7009	Live market-data snapshot, May 27, 2026 21:35:35 UTC. [1]	Current pre-split entry reference.
Split-adjusted equivalent	$5.61	Author calculation: `$0.7009 x 8`. [1][2]	The June 1 quote reference if price does not move.
Pre-split common shares outstanding	~79.5 million	SCYNEXIS split release, May 22, 2026. [2]	Basic equity value should use the updated denominator, not a stale market-cap feed.
Post-split common shares outstanding	~9.9 million	SCYNEXIS split release. [2]	Defines post-split float optics.
Basic equity value at current price	~$55.7 million	Author calculation from price and company share count. [1][2]	Still below the documented cash-and-investments runway frame.
Cash, cash equivalents and investments	$72.4 million	Q1 update and Form 10-Q, March 31, 2026. [3][7]	Balance-sheet anchor before the April 1 proceeds.
Additional proceeds received April 1	~$16.0 million	Q1 update. [3]	Raises the post-April runway frame to about $88.4 million before burn.
Current liabilities	$15.9 million	Q1 balance sheet. [3][7]	Needed to avoid pretending cash equals distributable value.
Total liabilities	$36.3 million	Q1 balance sheet, including warrant liabilities. [3][7]	Important, but warrant liabilities are mark-to-market accounting, not a cash debt maturity.
Q1 operating expenses	$16.9 million	Q1 update and Form 10-Q. [3][7]	Burn risk is real and must reduce any naive cash-floor argument.

This is not a liquidation thesis. Cash is not a floor. Biotech cash can and often does become research spend.

The mispricing is different: at the current quote, the market is treating the split optics as more informative than a funded runway that management says runs to mid-2029, one year beyond the anticipated completion of the SCY-770 Phase 2 study. [3]

Positioning

Direct positioning data is missing. I did not verify current borrow cost, short interest, options open interest, or institutional flow during this run.

The positioning evidence is therefore structural, not granular:

Sub-dollar biotech screens often exclude funds that cannot own low-price securities or do not want reverse-split event risk.
Reverse splits invite mechanical selling from holders who treat the event as a capital-raise warning.
The live quote feed’s stale market-cap denominator can understate the company’s basic equity value and still distort the screen because the market cap looks more distressed than it is.
The company has just completed a financing, so the next few sessions may separate forced split selling from investors willing to underwrite the runway.

The strongest version of the long thesis does not require proving a short squeeze. It only requires the market to stop treating the split as the whole story.

Catalyst

Catalyst 1: May 29 split effectiveness. The 1-for-8 reverse split becomes effective at 4:05 p.m. ET on May 29, 2026. [2]

Catalyst 2: June 1 split-adjusted trading. The stock begins split-adjusted Nasdaq trading on June 1. Post-split screens will show a roughly $5.61 stock if price is unchanged, not a sub-dollar ticker. [1][2]

Catalyst 3: Q3 2026 IV SCY-247 topline data. SCYNEXIS says it plans to report topline data from the intravenous SCY-247 Phase 1 study in Q3 2026. [3]

Catalyst 4: Q4 2026 SCY-770 Phase 2 start. The company expects to begin a Phase 2 proof-of-concept study of SCY-770 in ADPKD patients in Q4 2026, with an early efficacy readout expected in the second half of 2027. [3]

Catalyst 5: BREXAFEMME relaunch economics. SCYNEXIS says GSK remains committed to relaunching BREXAFEMME and that SCYNEXIS could receive up to approximately $146 million in annual net sales milestones. This is contingent value, not present cash, but it means the antifungal license is not dead paper. [3]

Payoff Map

One possible expression is long SCYX common stock through the split-adjusted trading window. The thesis is not that reverse splits are bullish. It is that this split may be over-explaining a stock that now has a funded runway and multiple visible clinical calendars.

I reject a first-line options expression in this run because I did not verify a live option chain, open interest, strike liquidity, or bid-ask spreads. I also reject waiting until after June 1 as the base expression because the specific dislocation is the transition from sub-dollar optics to post-split screens.

The main downside is clean: if the market treats the reverse split as a prelude to more dilution, the stock can keep falling even if the cash exists. The March financing included warrants and pre-funded warrants. Fully diluted share math is less attractive than basic share math, although common-warrant exercise would also bring in cash. [3]

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Time Horizon	Conditions Required	Evidence Quality
Top Case	30%	$1.10 pre-split, or $8.80 split-adjusted	+57.0%	1 to 8 weeks	Post-split selling is absorbed, investors re-anchor to funded runway, and Q3 SCY-247 optionality starts to matter before more dilution fear returns.	Medium
Base Case	45%	$0.86 pre-split, or $6.88 split-adjusted	+22.7%	1 to 6 weeks	June 1 trading removes sub-dollar optics, the stock trades back toward a partial cash-runway frame, and no negative financing or trial update hits immediately.	Medium / High
Bottom Case	25%	$0.55 pre-split, or $4.40 split-adjusted	-21.5%	Days to 6 weeks	Reverse-split sellers dominate, biotech microcap liquidity deteriorates, and the market keeps treating the company as a future diluter despite the runway claim.	Medium
Invalidation / Stop Condition	n/a	Sustained trade below $0.50 pre-split equivalent, or new financing language that weakens the mid-2029 runway claim	Thesis break	Immediate through Q3 2026	The market is no longer merely discounting split optics; it is correctly anticipating capital pressure, pipeline impairment, or worse burn.	Medium

Probability-weighted expected value: 0.30 x $1.10 + 0.45 x $0.86 + 0.25 x $0.55 = $0.8545, or about +21.9% versus the $0.7009 current price. This is a scenario frame, not a model output. It excludes taxes, commissions, slippage, and the possibility that reverse-split selling overwhelms fundamentals.

Current market price / level: SCYX $0.7009 pre-split, equal to about $5.61 split-adjusted. [1][2]

Timestamp: Price checked May 27, 2026 at 21:35:35 UTC; article compiled May 28, 2026 07:13 Asia/Ho_Chi_Minh.

Primary instrument: SCYNEXIS common stock, SCYX.

Alternative expressions considered: Wait until June 1 post-split trading; avoid until SCY-247 Q3 data; long common with a tighter stop; call options or call spreads if a liquid chain exists. Options were not selected because live chain liquidity was not verified.

Confidence: Medium. The balance-sheet and split facts are strong. The post-split flow inference is only partly observable.

What Would Prove This Wrong

This fails if SCYX trades below $0.50 pre-split equivalent on meaningful volume after the split without a fast recovery.

It also fails if SCYNEXIS signals that runway to mid-2029 is no longer a reasonable claim, if operating spend accelerates materially above the Q1 run rate without non-dilutive funding, if GSK relaunch language weakens, or if SCY-247 or SCY-770 timelines slip enough to pull the runway back inside the next major data window. [3]

The subtler failure is a liquidity failure: the thesis can be directionally right and still lose money if post-split holders sell indiscriminately and the bid disappears. That is why the trade expression must use common-stock sizing and limit-order discipline rather than leverage.

Risk Audit

Strongest counterargument: Reverse-split biotech weakness is not irrational. These events often happen because the company has already lost investor trust. A funded runway can still be worth less than cash if the market expects management to spend it on programs with weak odds.

Most fragile assumption: The fragile assumption is that post-split trading changes the marginal buyer. It may not. The same sellers may keep selling, just at a higher nominal price.

What the market may already know: The market may already understand the runway and still discount it because Q1 operating expenses were $16.9 million, the company has no current product revenue in the quarter, and the key SCY-770 efficacy readout is not expected until the second half of 2027. [3]

What could make the trade lose money even if the thesis is directionally right: The stock can fall on reverse-split flow before runway buyers appear. It can also trade down if small-cap biotech risk appetite deteriorates or if investors focus on warrants and future financing over cash.

Liquidity / execution risks: The stock is a low-priced microcap biotech with split-date mechanics. Slippage, wide spreads, and odd broker adjustments are plausible. Use limit orders if expressing the idea.

Leverage risks: Do not use leverage for this setup. The price path can gap around the split.

Information reliability risks: Price, split, share count, and cash figures are sourced. Live borrow, short-interest, and options-chain data were not verified.

Invalidation trigger: Sustained trade below $0.50 pre-split equivalent, a materially weaker runway statement, a delayed clinical calendar, or new financing terms that transfer upside away from common holders.

Publish / revise / reject recommendation: Publish as a medium-confidence deep dive. The idea has a real event clock and a documented balance-sheet disagreement, but it is not high-confidence enough for an options-first expression.

Bottom Line

SCYX is ugly for the obvious reason: it needs a reverse split to keep its Nasdaq listing clean. The better question is whether the market is using that ugliness as a shortcut. At $0.7009, the common prices a distressed biotech screen more than a company that says it has cash and investments through mid-2029, a split-adjusted quote above $5, and two program calendars that can matter before the runway ends. The trade is not buying the split. It is buying the chance that the split stops hiding the runway.

Best Trade Strategy

Best trade: Long SCYX common stock.

Direction: Long.

Preferred instrument: SCYX common shares.

Common-stock stance: Common is the cleanest expression because the thesis is about the equity market re-pricing the balance sheet and runway after split-adjusted trading begins.

Options stance: Options are not the preferred expression in this run. I did not verify live option-chain liquidity, open interest, or bid-ask spreads. If a liquid chain exists, a defined-risk call spread could fit the re-rating thesis better than outright calls, but that requires live chain verification.

Entry reference: $0.7009 pre-split, checked May 27, 2026 at 21:35:35 UTC. Split-adjusted equivalent is about $5.61. [1][2]

Take-profit levels: First TP near $0.86 pre-split equivalent, or $6.88 split-adjusted. Stretch TP near $1.10 pre-split equivalent, or $8.80 split-adjusted.

Stop-loss / invalidation: Thesis break below $0.50 pre-split equivalent on sustained volume, or any company update that weakens the mid-2029 runway statement.

Time horizon: Days to 8 weeks for the split re-rating. Longer holders are underwriting SCY-247 Q3 2026 data and SCY-770 Phase 2 progress, which is a different risk profile.

Execution risks: Reverse-split settlement mechanics, spread widening, low-liquidity trading, post-split forced selling, warrant overhang, and biotech tape risk.

Do-not-trade conditions: Do not trade if the price gaps above $1.05 pre-split equivalent before entry without new fundamental evidence, if spreads become disorderly around the split, if the company files new dilutive financing terms, or if broker handling of the split is unclear.

Monitoring checklist:

Watch Item	Why It Matters
May 29 split effectiveness	Confirms the event clock.
June 1 split-adjusted opening range	Shows whether the post-split screen changes buyers or simply concentrates sellers.
Any updated share-count or warrant disclosure	Prevents stale per-share cash math.
Q3 2026 SCY-247 IV topline timing	First visible program catalyst after the split.
SCY-770 Phase 2 start timing in Q4 2026	Tests whether runway aligns with the pipeline calendar.
GSK BREXAFEMME relaunch language	Non-dilutive milestone optionality depends on the relaunch path.

Research Quality Scorecard

Criterion	Score	Evidence note
Market disagreement	5	The article isolates a specific split-optics versus funded-runway disagreement, using current price, company share count, split timing, and cash runway.
Evidence base	5	Core facts use the live market-data snapshot, SCYNEXIS reverse-split release, Q1 corporate update, and SEC filing context.
Positioning and flows	3	Direct borrow, short-interest, and options-flow data are missing; the positioning claim is structural and labeled as such.
Catalyst path	4	The May 29 split and June 1 split-adjusted trading are immediate, while Q3 and Q4 program catalysts extend the window.
Payoff architecture	4	Top, base, and bottom cases are explicit and EV is computed, but biotech and split-flow tails remain high.
Invalidation discipline	4	The article defines price, runway, financing, and clinical-calendar invalidation triggers.
Differentiated insight	4	The non-obvious point is that stale market-cap screens and split stigma may be overpowering the company’s own financed runway.
Client value	5	Useful even without a trade because it warns against treating reverse splits as a sufficient thesis in either direction.
Total	34	Publishable deep dive, medium confidence.

Sources

Ref	Source	Use
[1]	Live market-data snapshot checked during this run for `SCYX`, `LNTH`, `CGBD`, and `FONR`; `SCYX` price timestamp May 27, 2026 21:35:35 UTC	Current market levels and candidate-screen prices.
[2]	SCYNEXIS announces one-for-eight reverse stock split, May 22, 2026	Split ratio, effective time, June 1 trading start, share-count change, Nasdaq compliance purpose.
[3]	SCYNEXIS reports first-quarter 2026 financial results and corporate update, May 11, 2026	Cash and investments, April 1 proceeds, cash runway, expenses, clinical calendar, GSK milestone language.
[4]	Reuters summary of reported Curium interest in Lantheus, May 22, 2026	Candidate ranking only.
[5]	Carlyle Secured Lending preliminary proxy summary for below-NAV issuance vote	Candidate ranking only.
[6]	FONAR cash-merger proxy summary for May 28 meeting	Candidate ranking only.
[7]	SCYNEXIS Form 10-Q for the quarter ended March 31, 2026	SEC filing backup for Q1 balance sheet, liabilities, expenses, and share-count context.

Publication Audit

Gate	Status	Note
Mispricing specific	Yes	Split optics versus financed runway and updated share count.
Evidence beyond narrative	Yes	Price, split release, Q1 update, balance sheet, and catalyst calendar.
Positioning supported or uncertain	Yes	Direct flow data missing and labeled uncertain.
Catalyst or closing mechanism	Yes	May 29 split and June 1 split-adjusted trading.
Downside honest	Yes	Reverse-split selling, burn, warrants, and future dilution risk included.
Strongest counterargument	Yes	Reverse splits often correctly signal weak capital-market access.
Useful if no trade	Yes	Explains why stale screen data can distort small-cap valuation.
Factual claims sourced	Yes	All non-obvious figures tied to sources or marked as author calculations.
Hype avoided	Yes	No certainty-of-profit or promotional framing.
Headline matches evidence	Yes	The article is about split stigma versus runway evidence.
Best opportunity right now explained	Yes	Ranking table documents rejected U.S. alternatives.
>5% move path explained	Yes	June 1 re-screening and post-split re-anchor path.
Surprise identified	Yes	Split may be hiding rather than creating the core value frame.
Targets and probabilities add to 100%	Yes	30% + 45% + 25% = 100%.
Scorecard included	Yes	Dedicated section included.
Reader tables remain Markdown	Yes	All tables are editable Markdown.
Optional table images	N/A	Not requested or created.
Illustration prompt inline	Yes	Included below.
Best Trade Strategy complete	Yes	Direction, instrument, common stance, options stance, TP, SL, timeline, risks, conditions, and checklist included.
Technical signals framed correctly	N/A	Thesis does not depend on technical signals.
Geographic lanes	N/A	User explicitly scoped this run to U.S. market only.
Japan lane	N/A	User explicitly scoped this run to U.S. market only.
Substack finish	N/A	User requested local article, commit, and push, not Substack publication.

Internal Audit Trail

Read the daily-post skill and /Volumes/SSD/mispricing-desk/AGENTS.md sections 1-9 and 17 before drafting.
Read automation memory before research. The last U.S. automation articles were BRNS, ASTS, GDOT, and NHIC.
Computed the current repo week folder from calendar-week convention as articles/2026-05/week-5/.
Scanned the current folder and repo-wide titles before selection.
Rejected duplicate or adjacent candidates including Aimco due-bill stub, TYG rights mechanics, FSK sponsor backstop, Allbirds/NewBird, FREVS liquidation, Seer below-cash bid, Gossamer recap, Stratus liquidation, and recent ASTS/GDOT/NHIC/BRNS articles.
Answered AGENTS.md section 6A-6E questions in drafting: mispricing, positioning, catalyst, payoff, and kill shot are represented in the main sections above.
No companion files, table images, or illustration files were created.

AI Illustration Prompt

Create a realistic, high-value, high-end editorial cover image for The Mispricing Desk about SCYNEXIS and its reverse-split mispricing. Show a precise institutional settlement desk at night, where a thin pre-split stock certificate labeled SCYX $0.7009 is being folded into a thicker post-split certificate labeled 1-for-8, June 1. Behind it, place a cool white laboratory balance scale: one side holds a brass weight marked $88.4m cash and investments runway, the other side holds a black card marked reverse split stigma. Add restrained scientific details tied to the company, including a small vial tray labeled SCY-247 Q3 and a clinical-study folder labeled SCY-770 Q4. The mood should be forensic, skeptical, and expensive, like an Economist or Bloomberg Markets cover about market mechanics and biotech survival math. Palette: graphite, surgical white, muted teal, brushed steel, and one amber timestamp accent. Avoid rockets, arrows, cartoon pills, meme biotech imagery, or generic candlestick charts. Include a subtle but clear watermark or engraved text reading The Mispricing Desk.